세계의 세포 및 유전자 치료 CDMO 시장 규모, 점유율, 동향 분석 : 상별, 제품별, 적응증별, 지역별, 부문별 예측(2025-2033년)

Cell And Gene Therapy CDMO Market Size, Share & Trends Analysis Report By Phase, By Product, By Indication, By Region, And Segment Forecasts, 2025 - 2033

US $ 5,950 ￦ 8,704,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 10,167,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 13,093,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

세포·유전자 치료 CDMO 시장 요약

세계의 세포·유전자 치료 CDMO 시장 규모는 2024년에 43억 1,000만 달러로 평가되며, 2033년에는 271억 2,000만 달러에 달하며, 2025-2033년 CAGR은 23.03%로 성장할 것으로 예측됩니다.

세포 및 유전자 치료 제품 포트폴리오의 확대, 희귀질환에 대한 연구자들의 관심 증가, 민관 모두 연구개발에 대한 막대한 투자 등이 이 산업을 주도하고 있습니다.

또한 세포-유전자치료 관련 아웃소싱 서비스에 대한 수요 증가, 암 등 만성질환의 유병률 증가, M&A 활동의 급증, 세포-유전자치료제 개발 프로세스 전반에서 진행 중인 기술 혁신 등도 성장을 촉진하고 있습니다. 이 시장은 주로 생명공학 산업과 제약업계의 세포-유전자 치료제(CGT)에 대한 연구개발 자금과 투자 증가에 의해 주도되고 있습니다. 세포-유전자 치료는 암, 유전성 질환, 특정 감염성 질환 등 다양한 질환의 치료에 큰 잠재력을 가지고 있습니다. 따라서 이러한 치료법의 큰 가능성으로 인해 혁신적인 세포 및 유전자 치료법의 개발 및 발견에 대한 민간 및 공공 부문의 관심이 크게 증가하고 있습니다. 현재 대부분의 대형 제약사들은 시장에서 확고한 입지를 구축하기 위해 CGT에 투자하고 있습니다. 특히 생명과학 분야에서는 벤처캐피털의 투자가 크게 증가하고 있습니다.

또한 임상 파이프라인 증가와 생산에 필요한 전문 지식 및 인프라에 대한 아웃소싱에 대한 의존도가 높은 것도 시장 성장을 가속하는 요인으로 작용하고 있습니다. clinicaltrials.org가 발표한 자료에 따르면 현재 진행 중인 세포-유전자치료제 임상시험은 2,000건 이상이며, 개발 단계에 따라 초기 단계에서 후기 단계로 넘어갈 때마다 바이러스 벡터, 플라스미드, 임상용 세포 가공에 대한 수요가 증가하고 있습니다. 증가하고 있습니다. 2023-24년 FDA의 겸상적혈구증 치료제 Casgevy와 Duchenne 근이영양증 치료제 Elevidys의 FDA 승인과 EMA의 혈우병 A 치료제 Roctavian의 승인은 상업화 단계에 진입하는 첨단 치료제가 증가하고 있다는 것을 보여줍니다. 첨단 치료제가 상업화 단계에 진입하고 있다는 점을 강조하고 있습니다. 이러한 혁신을 개발하고 있는 대부분의 중소 바이오기업은 대규모 GMP 시설이 부족하므로 CDMO와의 제휴가 환자들에게 전달하기 위해 필수적입니다. 이러한 급증에 대응하기 위해 론자, 캐터런트, 우시 첨단 테라퓨틱스, 써모피셔 등 주요 기업은 바이러스 벡터 및 세포치료제 생산능력 확대에 많은 투자를 하고 있으며, 지속적인 아웃소싱 수요에 대한 강한 자신감을 드러내고 있습니다. 이러한 요인들이 결합되어 승인 속도가 빨라지고, 파이프라인이 풍부해지고, 제조 수요가 사내 생산 능력을 초과함에 따라 시장은 지속적으로 높은 성장세를 보일 것으로 예측됩니다.

목차

제1장 분석 방법·범위

제2장 개요

제3장 세포·유전자 치료 CDMO 시장 : 변동 요인·동향·범위

• 시장 계통 전망
• 세포·유전자 치료 CDMO 시장 역학
• 기술적 상황
• 가격 모델 분석
• 세포·유전자 치료 CDMO 시장 : 분석 툴

제4장 세포·유전자 치료 CDMO 시장 : 상별(단계별) 추정·동향 분석

• 부문 대시보드
• 세계의 세포·유전자 치료 CDMO 시장 : 변동 분석, 상별
• 세계의 세포·유전자 치료 CDMO 시장 규모와 동향 분석 : 상별(2021-2033년)
• 전임상
• 임상

제5장 세포·유전자 치료 CDMO 시장 : 제품별 추정·동향 분석

• 부문 대시보드
• 세계의 세포·유전자 치료 CDMO 시장 : 변동 분석, 제품별
• 세계의 세포·유전자 치료 CDMO 시장 규모와 동향 분석 : 제품별(2021-2033년)
• 유전자 치료
  • 생체외
  • 생체내
• 유전자 개변 세포치료
  • CAR T 세포치료
  • CAR-NK 세포치료
  • TCR-T 세포치료
  • 기타
• 세포치료

제6장 세포·유전자 치료 CDMO 시장 : 적응증별 추정·동향 분석

• 부문 대시보드
• 세계의 세포·유전자 치료 CDMO 시장 : 변동 분석, 적응증별
• 세계의 세포·유전자 치료 CDMO 시장 규모와 동향 분석 : 적응증별(2021-2033년)
• 종양
• 감염증
• 신경질환
• 희귀질환
• 기타

제7장 세포·유전자 치료 CDMO 시장 : 지역별 추정·동향 분석(서비스별, 모델 유형별, 최종 용도별)

• 시장 대시보드 : 지역별
• 세계 시장 스냅숏 : 지역별
• 시장 규모 예측과 동향 분석(2021-2033년)
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트
  • 오만
  • 카타르

제8장 경쟁 구도

• 기업 분류
• 세포·유전자 치료 CDMO 시장 점유율 분석(2024년)
• 기업 개요
  • Lonza
  • Catalent, Inc
  • Cytiva
  • Samsung Biologics
  • Thermo Fisher Scientific Inc.
  • Novartis AG
  • WuXi AppTec
  • AGC Biologics
  • OmniaBio
  • Charles River Laboratories
  • Rentschler Biopharma SE

KSA

영문 목차

영문목차

Cell And Gene Therapy CDMO Market Summary

The global cell and gene therapy CDMO market size was valued at USD 4.31 billion in 2024 and is projected to reach USD 27.12 billion by 2033, growing at a CAGR of 23.03% from 2025 to 2033. The industry is driven by the expanding portfolio of cell and gene therapy products, increased researcher attention on rare diseases, and substantial investments from both public and private sectors in research and development.

The rising demand for outsourced services related to cell and gene therapies, the increasing prevalence of chronic ailments such as cancer, a surge in mergers & acquisitions activities, and ongoing technological innovations throughout the cell and gene therapy development process are also fueling the growth. The market is primarily driven by the increased R&D funding and investments in cell and gene therapeutics (CGT) by the biotechnology and pharmaceutical industries. Cell and gene therapies hold significant potential in treating a wide range of diseases, including cancer, genetic disorders, and certain infectious diseases. Hence, owing to the great potential of these therapeutics, there has been a considerable increase in interest from both private and public sectors in the development and discovery of innovative cell and gene therapies. Most big pharmaceutical companies are now investing in CGT to create a strong position in the market. There has been a considerable increase in venture capital investments, especially in the life sciences sector.

Furthermore, an increased clinical pipeline and persistent reliance on outsourcing due to the specialized expertise and infrastructure required for production are also factors which is driving market growth. According to the data published by clinicaltrials.org there are currently over 2,000 ongoing clinical trials in cell and gene therapies that are progressing through development stages, and each transition from early to late phase amplifies the demand for viral vectors, plasmids, and clinical-grade cell processing. FDA approvals of novel treatments such as Casgevy for sickle cell disease and Elevidys for Duchenne muscular dystrophy in 2023-24, alongside EMA's approval of Roctavian for hemophilia A, highlight the growing momentum of advanced therapies entering the commercial stage. Most small and mid-sized biotech firms pioneering these innovations lack large-scale GMP facilities, making partnerships with CDMOs essential to reach patients. To meet this surge, leading players like Lonza, Catalent, WuXi Advanced Therapies, and Thermo Fisher have invested heavily in expanding viral vector and cell therapy capacity, indicating strong confidence in sustained outsourcing demand. Together, these drivers position the market for sustained high growth as approvals accelerate, pipelines deepen, and manufacturing needs outpace in-house capabilities.

Global Cell And Gene Therapy CDMO Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global cell and gene therapy CDMO market report based on phase, product, indication, and region.

• Phase Outlook (Revenue, USD Million, 2021 - 2033)
• Pre-clinical
• Clinical
• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Gene Therapy
  • Ex-vivo
  • In-vivo
• Gene-Modified Cell Therapy
  • CAR T-cell therapies
  • CAR-NK cell therapy
  • TCR-T cell therapy
  • Others
• Cell Therapy
• Indication Outlook (Revenue, USD Million, 2021 - 2033)
• Oncology
• Infectious Diseases
• Neurological disorders
• Rare Diseases
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Norway
  • Sweden
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Oman
  • Qatar

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Value chain based analysis (Model 2)
  • 1.7.3. Multivariate Analysis (Model 3)
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Cell And Gene Therapy CDMO Market: Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Ancillary Market Outlook
• 3.2. Cell And Gene Therapy CDMO Market Dynamics
  • 3.2.1. Market Driver Impact Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Technological Landscape
• 3.4. Pricing Model Analysis
• 3.5. Cell And Gene Therapy CDMO Market: Analysis Tools
  • 3.5.1. Porter's Five Forces Analysis
  • 3.5.2. PESTEL Analysis

Chapter 4. Cell And Gene Therapy CDMO Market: Phase Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Cell And Gene Therapy CDMO Market Phase Movement Analysis
• 4.3. Global Cell And Gene Therapy CDMO Market Size & Trend Analysis, by Phase, 2021 to 2033 (USD Million)
• 4.4. Pre-clinical
  • 4.4.1. Pre-clinical Market Estimates and Forecasts, 2021 - 2033 (USD million)
• 4.5. Clinical
  • 4.5.1. Clinical Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Cell And Gene Therapy CDMO Market: Product Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Cell And Gene Therapy CDMO Market Product Type Movement Analysis
• 5.3. Global Cell And Gene Therapy CDMO Market Size & Trend Analysis, by Product Type, 2021 to 2033 (USD Million)
• 5.4. Gene Therapy
  • 5.4.1. Gene Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.2. Ex-vivo
    • 5.4.2.1. Ex-vivo Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.3. In-vivo
    • 5.4.3.1. In-vivo Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Gene-Modified Cell Therapy
  • 5.5.1. Gene-Modified Cell Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.2. CAR T-cell therapies
    • 5.5.2.1. CAR T-cell therapies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.3. CAR-NK cell therapy
    • 5.5.3.1. CAR-NK cell therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.4. TCR-T cell therapy
    • 5.5.4.1. TCR-T cell therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.5. Other
    • 5.5.5.1. Other Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Cell Therapy
  • 5.6.1. Cell Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Cell And Gene Therapy CDMO Market: Indication Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Cell And Gene Therapy CDMO Market Indication Movement Analysis
• 6.3. Global Cell And Gene Therapy CDMO Market Size & Trend Analysis, by Indication, 2021 to 2033 (USD Million)
• 6.4. Oncology
  • 6.4.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Infectious Diseases
  • 6.5.1. Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Neurological disorders
  • 6.6.1. Neurological disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Rare Diseases
  • 6.7.1. Rare Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.8. Others
  • 6.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Cell And Gene Therapy CDMO Market: Regional Estimates & Trend Analysis by Service, Model Type, End Use

• 7.1. Regional Market Dashboard
• 7.2. Global Regional Market Snapshot
• 7.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 7.4. North America
  • 7.4.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Competitive Scenario
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Competitive Scenario
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Competitive Scenario
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Europe
  • 7.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Competitive Scenario
    • 7.5.5.3. Regulatory Framework
    • 7.5.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Competitive Scenario
    • 7.5.6.3. Regulatory Framework
    • 7.5.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.7. Denmark
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Competitive Scenario
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.8. Sweden
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Competitive Scenario
    • 7.5.8.3. Regulatory Framework
    • 7.5.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.9. Norway
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Competitive Scenario
    • 7.5.9.3. Regulatory Framework
    • 7.5.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Competitive Scenario
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.5. Australia
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Competitive Scenario
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.6. South Korea
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Competitive Scenario
    • 7.6.6.3. Regulatory Framework
    • 7.6.6.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.7. Thailand
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Competitive Scenario
    • 7.6.7.3. Regulatory Framework
    • 7.6.7.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.8. MEA
  • 7.8.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Competitive Scenario
    • 7.8.2.3. Regulatory Framework
    • 7.8.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Competitive Scenario
    • 7.8.3.3. Regulatory Framework
    • 7.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Competitive Scenario
    • 7.8.4.3. Regulatory Framework
    • 7.8.4.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Competitive Scenario
    • 7.8.5.3. Regulatory Framework
    • 7.8.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.6. Oman
    • 7.8.6.1. Key Country Dynamics
    • 7.8.6.2. Competitive Scenario
    • 7.8.6.3. Regulatory Framework
    • 7.8.6.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.7. Qatar
    • 7.8.7.1. Key Country Dynamics
    • 7.8.7.2. Competitive Scenario
    • 7.8.7.3. Regulatory Framework
    • 7.8.7.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company Categorization
• 8.2. Cell And Gene Therapy CDMO Market Share Analysis, 2024
• 8.3. Company Profiles
  • 8.3.1. Lonza
    • 8.3.1.1. Company overview
    • 8.3.1.2. Financial performance
    • 8.3.1.3. Product benchmarking
    • 8.3.1.4. Strategic initiatives
  • 8.3.2. Catalent, Inc
    • 8.3.2.1. Company overview
    • 8.3.2.2. Financial performance
    • 8.3.2.3. Product benchmarking
    • 8.3.2.4. Strategic initiatives
  • 8.3.3. Cytiva
    • 8.3.3.1. Company overview
    • 8.3.3.2. Financial performance
    • 8.3.3.3. Product benchmarking
    • 8.3.3.4. Strategic initiatives
  • 8.3.4. Samsung Biologics
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Thermo Fisher Scientific Inc.
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Novartis AG
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. WuXi AppTec
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. AGC Biologics
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. OmniaBio
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Charles River Laboratories
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Rentschler Biopharma SE
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives

관련자료